Breaking News
Investing Pro 0
Cyber Monday Extended SALE: Up to 60% OFF InvestingPro+ CLAIM OFFER

The Cannabis Craze

By Zacks Investment ResearchStock MarketsMay 17, 2019 07:03AM ET
www.investing.com/analysis/the-cannabis-craze-200422729
The Cannabis Craze
By Zacks Investment Research   |  May 17, 2019 07:03AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
WEED
+8.64%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ACB
+2.89%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BTC/USD
-0.71%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
TLRY
+7.75%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 


Aurora Cannabis (TO:ACB) , Tilray (NASDAQ:TLRY) , and Canopy Growth Company (NYSE:CGC) are a few of the hyped up marijuana stocks we saw hit the markets in 2018. The “Cannabis Craze” had everyone and their brother buying up marijuana stocks. These cannabis stocks didn’t have enough free-floating shares to cover the massive amount of buy interest leading them to skyrocket at the end of 2018 far above their fair value.

Canadian Legalization

Investors jumped into these stocks on the announcement of Canada legalizing recreational marijuana, which was official on October 17th of last year, on the hopes that the United States would follow suit promptly.

The logic behind investing in a Canadian cannabis company isn’t entirely flawed. These companies have established infrastructure and economies to scale that would allow them to quickly address the needs of American pot smokers if federal legalization were to take place in the US. This would represent a considerable upside potential for any marijuana company already in operation.

Unfortunately, I believe that the optimism of US weed legalization is somewhat misplaced considering the complexity of our federal legislative system would delay this legalization for years. Even though individual states have been able to legalize marijuana, it will be many years before it is federally legalized, leaving all the growth expectations for these Canadian cannabis stocks on the back burner for an indefinite amount of time.

Since the initial rally in marijuana stocks, most of these equities have plunged. Tilray (TLRY) is down over 72% since mid-October, Canopy Growth Company (CGC) is down about 22% in the same time frame, and ACB is down about 25%. Aurora hasn’t fallen as fast as Tilray because the firm has been showing accelerating topline growth, but unfortunately, the firm can’t keep its profits above ground level with losses on the income statement the last two quarters.

Trend Trading Downside

Cannabis stocks are a new trend, and investors aren’t entirely sure how to value these firms. Usually, new and exciting stocks and securities attract a lot of interest because of the awe factor that is associated with an intriguing new industry.

We saw it in 1999 with the dotcom bubble. Everyone wanted to get into these soaring tech stocks and it pushed the valuation way beyond their fair value. As we all know, this eventually led to the entire stock market tanking and sent the US into a temporary recession.

More recently cryptocurrencies were all the talk, not just with investors but with everyone, exchanges even creating futures for this new hot commodity. The prices of these cryptos proliferated over a short period of time with Bitcoin exploding 2,273% in less than one year during 2017. Once the hype had diminished, and investors realized that these currencies weren’t being utilized the value of them fell significantly.

This is what I believe is happening with these marijuana stocks. Investors are overzealous about getting into a cannabis stock, not caring about the valuation. I believe a further realization will hit and these stocks could see a larger downside.

Valuation

In my opinion, these cannabis stocks are still grossly overvalued when assessing their multiples. Too much of US legalization is hinged on these firms valuations and like I mentioned above, I don’t see this happening for years to come. ACB is currently trading at 67x price/sales, TLRY at 76x P/S and CGC at 77x P/S which are all astronomical multiples considering that the overall markets P/S is below 3x and the medical products industry is just below 4x P/S. Price to sales is the only multiple I can use for these firms because every other multiple is negative (considering their inability to turn an operating profit).

Aura isn’t expected to turn a profit until 2021. Even those estimates have been revised down twice in the past 30 days and could turn negative with this continued pessimism. The firm is expected to lose 250% in EPS this year compared to 2018. Sell-side analysts continue to lower expectation for this firm pushing ACB into a Zacks Rank - #4 (Sell).

Tilray is also not expected to see profits until 2021 and has had multiple downward adjusted EPS revisions over the past 90 days leading TLRY to be a Zacks Rank - #4 (Sell)

Canopy Growth is expected to report a 2019 EPS that’s 238% less than last year. Canopy may not even turn a profit until 2022, according to some analysts.

Take Away

These marijuana stocks are extremely speculative and I would be hard pressed to call them anything but a gamble. The fair valuation of stocks in a new industry is somewhat ambigous making it very difficult for a value investor to justify buying. These stocks may have room in a well diversified portfolio if the individual is willing to put on some risk. I personally will be staying away from these and looking to invest in something with sustainable returns, reasonable valuations, and a longer industry track record. Once this industry is more established and these firms can show long term profitablity then I will reassess.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Aurora Cannabis Inc. (ACB): Free Stock Analysis Report

Tilray, Inc. (TLRY): Free Stock Analysis Report

Canopy Growth Corporation (CGC): Free Stock Analysis Report

Original post

Zacks Investment Research
The Cannabis Craze
 

Related Articles

Declan Fallon
Markets Consolidate Gains By Declan Fallon - Dec 02, 2022

Thursday's action did me favor and ensured there was no significant give-back to Wednesday's gains. What was important (for me) was that gains managed to negate the lingering...

The Cannabis Craze

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email